Biochemical Markers of Bone Metabolism in Metastatic Bone Disease

1994 ◽  
pp. 109-126 ◽  
Author(s):  
M. J. Seibel ◽  
I. Lambrinoudaki ◽  
A. Zipf
Keyword(s):  
Bone Metabolism ◽  
Bone Disease ◽  
Biochemical Markers ◽  
Metastatic Bone Disease

Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients

2002 ◽  
Vol 325 (1-2) ◽  
pp. 51-57 ◽  
Author(s):  
Michael G Alexandrakis ◽  
Freda H Passam ◽  
Niki Malliaraki ◽  
Constantinos Katachanakis ◽  
Despina S Kyriakou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Metabolism ◽  
Bone Disease ◽  
Biochemical Markers ◽  
Clinical Parameters

scholarly journals Bone remodeling markers and their role in oncology

2021 ◽  
pp. 120-132
Author(s):  
O. O. Golounina ◽  
Zh. E. Belaya
Keyword(s):  
Bone Metastases ◽  
Bone Metabolism ◽  
Bone Remodeling ◽  
Bone Disease ◽  
Biochemical Markers ◽  
Pain Syndrome ◽  
Diagnostic Tools ◽  
Bone Remodeling Markers ◽  
Skeletal Complications

Bone metastases are a common complication of cancer. Patients with bone metastases may have experienced skeletal-related events, such as hypercalcemia, pathological fractures, pain syndrome of varying intensity, spinal cord compression with negative effects on the quality of life. Current diagnostic tools have some limitations, such as high cost and limited availability in the distant areas, as well as falls negative and falls positive results. In this aspect, non-invasive sensitive markers of bone metabolism might give additional valuable information. Bone remodeling markers (N-terminal propeptide of type 1 collagen, osteocalcin, C-terminal telopeptide of type 1 collagen, etc.) have been used for a long time to predict the effectiveness of osteoporosis treatment; as additional risk factors for treatment initiation in patients with osteoporosis, in diagnostic search for secondary forms of osteoporosis; and as predictors of fracture in population studies. This review summarizes the clinically relevant biochemical markers of bone remodeling and the available evidence for their use in the metastatic bone disease in particularly in the diagnosis and prognosis of bone metastases risk and skeletal complications, predicting clinical outcomes, bone disease progression and overall survival. It has been shown that a sufficient suppression of bone remodeling biochemical markers while on treatment with bisphosphonates is associated with an improvement in survival and a decrease in the risk of skeletal complications in patients with bone metastases. New data may become a rational basis for wider use of bone metabolism markers in oncological practice. However, it is necessary to standardize and validate the determination of bone markers and verification of cut-off diagnostic values for their introduction into the routine clinical practice of patients with malignancy.

State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents

2005 ◽  
Vol 1 (3) ◽  
pp. 225-241 ◽  
Author(s):  
Ioannis Kanakis ◽  
Achilleas Theocharis ◽  
Argiris Noulas ◽  
Nikos Karamanos
Keyword(s):  
Bone Disease ◽  
Biochemical Markers ◽  
State Of The Art ◽  
Therapeutic Agents ◽  
Metastatic Bone Disease

Biochemical markers of bone turnover in patients with metastatic bone disease

1995 ◽  
Vol 41 (10) ◽  
pp. 1489-1494 ◽  
Author(s):  
L M Demers ◽  
L Costa ◽  
V M Chinchilli ◽  
L Gaydos ◽  
E Curley ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Disease ◽  
Biochemical Markers ◽  
Clinical Evidence ◽  
Metastatic Bone Disease ◽  
Z Score ◽  
Markers Of Bone Turnover

Abstract Several biochemical markers of bone formation and bone resorption have recently been developed. These markers have been evaluated for clinical utility in patients with metabolic bone disease, including Paget disease and osteoporosis, and for their potential use in cancer patients whose disease has metastasized to bone. We have evaluated seven markers of bone turnover in the plasma and urine of 94 patients with newly diagnosed or progressive malignancy with and without clinical evidence of bone metastases. As determined by a positive bone scan and (or) bone survey, 30 patients had metastases to bone; 51 patients had metastatic cancer without overt bony involvement; and 13 patients had local disease without bone metastases. To evaluate the predictive value of these markers in the metastatic population, we utilized a "Z-score" and logistic regression analysis to distinguish patients with documented bone metastatic disease from those patients without clinical evidence of bone metastases. The higher the Z-score, the better the marker predicts the presence of bone metastases. With this statistical approach, urine N-telopeptide measurements had the highest Z-score and the most significant association with the probability of bone metastases. Urine deoxypyridinoline was the second most predictive marker of bone metastases. Thus, biochemical markers of bone resorption might be of use to predict the presence of bone metastases in cancer patients and to monitor the efficacy of antiresorptive therapy in patients treated for metastatic bone disease.

Sign in / Sign up

Export Citation Format

Share Document